Inhibikase Therapeutics Past Earnings Performance
Past criteria checks 0/6
Inhibikase Therapeutics's earnings have been declining at an average annual rate of -38.9%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 38.2% per year.
Key information
-38.9%
Earnings growth rate
-9.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -38.2% |
| Return on equity | -173.3% |
| Net Margin | -7,304.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?
Jan 25
Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia
Aug 26Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M
Aug 12Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?
Aug 09Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation
Apr 06Inhibikase Therapeutics prices stock offering at $3
Jun 16Revenue & Expenses BreakdownBeta
How Inhibikase Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -19 | 7 | 0 |
| 30 Sep 23 | 0 | -19 | 7 | 0 |
| 30 Jun 23 | 0 | -19 | 7 | 0 |
| 31 Mar 23 | 0 | -18 | 6 | 0 |
| 31 Dec 22 | 0 | -18 | 6 | 0 |
| 30 Sep 22 | 0 | -19 | 7 | 0 |
| 30 Jun 22 | 0 | -19 | 7 | 0 |
| 31 Mar 22 | 2 | -17 | 7 | 0 |
| 31 Dec 21 | 3 | -15 | 7 | 0 |
| 30 Sep 21 | 3 | -11 | 6 | 0 |
| 30 Jun 21 | 3 | -7 | 5 | 0 |
| 31 Mar 21 | 2 | -5 | 4 | 0 |
| 31 Dec 20 | 1 | -3 | 3 | 0 |
| 30 Sep 20 | 1 | -2 | 2 | 0 |
| 30 Jun 20 | 1 | -3 | 2 | 0 |
| 31 Mar 20 | 1 | -5 | 4 | 0 |
| 31 Dec 19 | 1 | -6 | 4 | 0 |
| 30 Sep 19 | 2 | -7 | 5 | 0 |
| 31 Mar 19 | 4 | -4 | 3 | 0 |
| 31 Dec 18 | 4 | -2 | 3 | 0 |
| 30 Sep 18 | 3 | -1 | 2 | 0 |
| 31 Mar 18 | 3 | 0 | 1 | 0 |
| 31 Dec 17 | 2 | 0 | 1 | 0 |
| 31 Dec 16 | 1 | -1 | 1 | 0 |
Quality Earnings: IKT is currently unprofitable.
Growing Profit Margin: IKT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IKT is unprofitable, and losses have increased over the past 5 years at a rate of 38.9% per year.
Accelerating Growth: Unable to compare IKT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IKT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: IKT has a negative Return on Equity (-173.34%), as it is currently unprofitable.